FDA Inspection 982066 — Cadila Pharmaceuticals Limited
The FDA completed an inspection of Cadila Pharmaceuticals Limited on July 25, 2016 in Ankleshwar. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- July 25, 2016
- Fiscal Year
- 2016
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Ankleshwar (India)